Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RecruitingNCT05921253Phase: EARLY_PHASE1Started 2023-12-01
Summary
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study
Eligibility
Sex
ALL
Min Age
18 Years
Max Age
99 Years
Locations
Stephenson Cancer CenterOklahoma City, Oklahoma, United States
Stephenson Cancer Center- TulsaTulsa, Oklahoma, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT05921253